

ICMJE DISCLOSURE FORM

Date: 26/10/2026
Your Name: Cristina Asla-Ormaza
Manuscript Title: **Carcinomatosis Pericárdica: no siempre irreversible**

Manuscript Number (if known): <https://doi.org/10.7775/rac.es.v94.i5.21051>

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. “Related” means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The author’s relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

	Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)						
Time frame: Since the initial planning of the work								
1	<div>All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.</div> <div>☒ None</div> <div><table><tr><td></td><td></td></tr><tr><td></td><td></td></tr><tr><td colspan="2">Click the tab key to add additional rows.</td></tr></table></div>					Click the tab key to add additional rows.		
Click the tab key to add additional rows.								
Time frame: past 36 months								
2	<div>Grants or contracts from any entity (if not indicated in item #1 above).</div> <div>☒ None</div> <div><table><tr><td></td><td></td></tr><tr><td></td><td></td></tr></table></div>							

		<div> <div></div> <div></div> <div></div> </div>
3	Royalties or licenses	<div> ☒ None </div> <div> <div></div> <div></div> <div></div> </div>
4	Consulting fees	<div> ☒ None </div> <div> <div></div> <div></div> <div></div> <div></div> </div>
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	<div> ☒ None </div> <div> <div></div> <div></div> <div></div> </div>
6	Payment for expert testimony	<div> ☒ None </div> <div> <div></div> <div></div> <div></div> </div>
7	Support for attending meetings and/or travel	<div> ☒ None </div> <div> <div></div> <div></div> <div></div> </div>
8	Patents planned, issued or pending	<div> ☒ None </div>

		<div> <div></div> <div></div> <div></div> </div>
	• Participation on a Data Safety Monitoring Board or Advisory Board	<div> ☒ None </div> <div> <div></div> <div></div> <div></div> </div>
jump pju mp 10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	<div> ☒ None </div> <div> <div></div> <div></div> <div></div> </div>
11	Stock or stock options	<div> ☒ None </div> <div> <div></div> <div></div> <div></div> </div>
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	<div> ☒ None </div> <div> <div></div> <div></div> <div></div> </div>
13	Other financial or non-financial interests	<div> ☒ None </div> <div> <div></div> <div></div> <div></div> </div>

Please place an “X” next to the following statement to indicate your agreement:		
	I certify that I have answered every question and have not altered the wording of any of the questions on	

☒ this form.

12/13/2021 ICMJE Disclosure Form

A handwritten signature in black ink, appearing to read 'Cristine Aske Armeta', written in a cursive style.

Cristine
Aske
Armeta

ICMJE DISCLOSURE FORM

Date: 26/10/2026

Your Name: Mireia Codina-Prat

Manuscript Title: **Carcinomatosis Pericárdica: no siempre irreversible**

Manuscript Number (if known): <https://doi.org/10.7775/rac.es.v94.i5.21051>

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. “Related” means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The author’s relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)						
Time frame: Since the initial planning of the work									
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	<div style="background-color: #f2f2f2; padding: 5px;"> ☒ None </div> <table border="1" style="width: 100%; border-collapse: collapse; margin-top: 5px;"> <tr><td style="height: 20px;"></td><td style="height: 20px;"></td></tr> <tr><td style="height: 20px;"></td><td style="height: 20px;"></td></tr> <tr><td style="height: 20px;"></td><td style="height: 20px;"></td></tr> </table>							
Time frame: past 36 months									
2	Grants or contracts from any entity (if not indicated in item #1 above).	<div style="background-color: #f2f2f2; padding: 5px;"> ☒ None </div> <table border="1" style="width: 100%; border-collapse: collapse; margin-top: 5px;"> <tr><td style="height: 20px;"></td><td style="height: 20px;"></td></tr> <tr><td style="height: 20px;"></td><td style="height: 20px;"></td></tr> <tr><td style="height: 20px;"></td><td style="height: 20px;"></td></tr> </table>							
3	Royalties or licenses	<div style="background-color: #f2f2f2; padding: 5px;"> ☒ None </div> <table border="1" style="width: 100%; border-collapse: collapse; margin-top: 5px;"> <tr><td style="height: 20px;"></td><td style="height: 20px;"></td></tr> <tr><td style="height: 20px;"></td><td style="height: 20px;"></td></tr> <tr><td style="height: 20px;"></td><td style="height: 20px;"></td></tr> </table>							

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)								
4	Consulting fees	☒ None <table border="1" style="width: 100%;"> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> </table>									
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	☐ None <table border="1" style="width: 100%;"> <tr> <td>I have received speaker honoraria from Amgen Inc, Daiichi Sankyo and Astrazeneka.</td> <td></td> </tr> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> </table>		I have received speaker honoraria from Amgen Inc, Daiichi Sankyo and Astrazeneka.							
I have received speaker honoraria from Amgen Inc, Daiichi Sankyo and Astrazeneka.											
6	Payment for expert testimony	☒ None <table border="1" style="width: 100%;"> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> </table>									
7	Support for attending meetings and/or travel	☐ None <table border="1" style="width: 100%;"> <tr> <td>I recieved support for attending meetings, travel and accommodation support from Daiichi sankyo, Boehringer ingelheim, Bracco imaging S.p.A and Viatrix pharmaceuticales S.L.</td> <td></td> </tr> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> </table>		I recieved support for attending meetings, travel and accommodation support from Daiichi sankyo, Boehringer ingelheim, Bracco imaging S.p.A and Viatrix pharmaceuticales S.L.							
I recieved support for attending meetings, travel and accommodation support from Daiichi sankyo, Boehringer ingelheim, Bracco imaging S.p.A and Viatrix pharmaceuticales S.L.											
8	Patents planned, issued or pending	☒ None <table border="1" style="width: 100%;"> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> </table>									
	Participation on a Data Safety Monitoring Board or Advisory Board	☒ None <table border="1" style="width: 100%;"> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> </table>									
ju m p j u m p1 0	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	☒ None <table border="1" style="width: 100%;"> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> </table>									

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
11	Stock or stock options	☒ None	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	☒ None	
13	Other financial or non-financial interests	☒ None	

Please place an "X" next to the following statement to indicate your agreement:

☒ I certify that I have answered every question and have not altered the wording of any of the questions on this form.

MIREIA

CODINA PRAT

- 43633306Y

Firmado

digitalmente por

MIREIA CODINA PRAT

- 43633306Y

Fecha: 2026.10.27

12:08:52 +01'00'

ICMJE DISCLOSURE FORM

Date: 26/10/2026
Your Name: Ainhoa Echenique-Clerigué
Manuscript Title: **Carcinomatosis Pericárdica: no siempre irreversible**

Manuscript Number (if known): <https://doi.org/10.7775/rac.es.v94.i5.21051>

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. “Related” means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The author’s relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.


	Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)						
Time frame: Since the initial planning of the work								
1	<div>All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.</div> <div>☒ None</div> <div><table><tr><td></td><td></td></tr><tr><td></td><td></td></tr><tr><td colspan="2">Click the tab key to add additional rows.</td></tr></table></div>					Click the tab key to add additional rows.		
Click the tab key to add additional rows.								
Time frame: past 36 months								
2	<div>Grants or contracts from any entity (if not indicated in item #1 above).</div> <div>☒ None</div> <div><table><tr><td></td><td></td></tr><tr><td></td><td></td></tr></table></div>							

		<div> <div></div> <div></div> <div></div> </div>
3	Royalties or licenses	<div> ☒ None </div> <div> <div></div> <div></div> <div></div> </div>
4	Consulting fees	<div> ☒ None </div> <div> <div></div> <div></div> <div></div> <div></div> </div>
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	<div> ☒ None </div> <div> <div></div> <div></div> <div></div> </div>
6	Payment for expert testimony	<div> ☒ None </div> <div> <div></div> <div></div> <div></div> </div>
7	Support for attending meetings and/or travel	<div> ☒ None </div> <div> <div></div> <div></div> <div></div> </div>
8	Patents planned, issued or pending	<div> ☒ None </div>

		<div> <div></div> <div></div> <div></div> </div>
	• Participation on a Data Safety Monitoring Board or Advisory Board	<div> ☒ None </div> <div> <div></div> <div></div> <div></div> </div>
jump 10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	<div> ☒ None </div> <div> <div></div> <div></div> <div></div> </div>
11	Stock or stock options	<div> ☒ None </div> <div> <div></div> <div></div> <div></div> </div>
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	<div> ☒ None </div> <div> <div></div> <div></div> <div></div> </div>
13	Other financial or non-financial interests	<div> ☒ None </div> <div> <div></div> <div></div> <div></div> </div>
Please place an “X” next to the following statement to indicate your agreement:		
I certify that I have answered every question and have not altered the wording of any of the questions on		

☒ this form.

12/13/2021 ICMJE Disclosure Form



Ainhoa Echenique Clengue

ICMJE DISCLOSURE FORM

Date: 26/10/2026

Your Name: Irene Hernández-Pérez

Manuscript Title: **Carcinomatosis Pericárdica: no siempre irreversible**

Manuscript Number (if known): <https://doi.org/10.7775/rac.es.v94.i5.21051>

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. “Related” means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The author’s relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)						
Time frame: Since the initial planning of the work									
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	<div style="padding: 5px;"> ☒ None </div> <table border="1" style="width: 100%; border-collapse: collapse; margin-top: 5px;"> <tr><td style="height: 20px;"></td><td style="height: 20px;"></td></tr> <tr><td style="height: 20px;"></td><td style="height: 20px;"></td></tr> <tr><td style="height: 20px;"></td><td style="height: 20px;"></td></tr> </table>							
Time frame: past 36 months									
2	Grants or contracts from any entity (if not indicated in item #1 above).	<div style="padding: 5px;"> ☒ None </div> <table border="1" style="width: 100%; border-collapse: collapse; margin-top: 5px;"> <tr><td style="height: 20px;"></td><td style="height: 20px;"></td></tr> <tr><td style="height: 20px;"></td><td style="height: 20px;"></td></tr> <tr><td style="height: 20px;"></td><td style="height: 20px;"></td></tr> </table>							
3	Royalties or licenses	<div style="padding: 5px;"> ☒ None </div> <table border="1" style="width: 100%; border-collapse: collapse; margin-top: 5px;"> <tr><td style="height: 20px;"></td><td style="height: 20px;"></td></tr> <tr><td style="height: 20px;"></td><td style="height: 20px;"></td></tr> <tr><td style="height: 20px;"></td><td style="height: 20px;"></td></tr> </table>							

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
4	Consulting fees	☒ None	
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	☒ None	
6	Payment for expert testimony	☒ None	
7	Support for attending meetings and/or travel	<div>I have recieved support for attending meetings, travel and accommodation support from Laboratorios Farmacéuticos Rovi S.A, Amarin, Almirall, Pfizer, Novonordisk, Boehringer Ingelheim, Daiichi sankyo.</div>	
8	Patents planned, issued or pending	☒ None	
	Participation on a Data Safety Monitoring Board or Advisory Board	☒ None	
ju m p j u m p1 0	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	☒ None	

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
11	Stock or stock options	☒ None	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	☒ None	
13	Other financial or non-financial interests	☒ None	

Please place an "X" next to the following statement to indicate your agreement:

☒ I certify that I have answered every question and have not altered the wording of any of the questions on this form.



IRENE HERNANDEZ PEREZ

ICMJE DISCLOSURE FORM

Date: 26/10/2026

Your Name: Uxue Millet-Oyarzabal

Manuscript Title: **Carcinomatosis Pericárdica: no siempre irreversible**

Manuscript Number (if known): <https://doi.org/10.7775/rac.es.v94.i5.21051>

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. “Related” means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The author’s relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)						
Time frame: Since the initial planning of the work									
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	<div style="background-color: #f2f2f2; padding: 5px;"> ☒ None </div> <table border="1" style="width: 100%; border-collapse: collapse; margin-top: 5px;"> <tr><td style="height: 20px;"></td><td style="height: 20px;"></td></tr> <tr><td style="height: 20px;"></td><td style="height: 20px;"></td></tr> <tr><td style="height: 20px;"></td><td style="height: 20px;"></td></tr> </table>							
Time frame: past 36 months									
2	Grants or contracts from any entity (if not indicated in item #1 above).	<div style="background-color: #f2f2f2; padding: 5px;"> ☒ None </div> <table border="1" style="width: 100%; border-collapse: collapse; margin-top: 5px;"> <tr><td style="height: 20px;"></td><td style="height: 20px;"></td></tr> <tr><td style="height: 20px;"></td><td style="height: 20px;"></td></tr> <tr><td style="height: 20px;"></td><td style="height: 20px;"></td></tr> </table>							
3	Royalties or licenses	<div style="background-color: #f2f2f2; padding: 5px;"> ☒ None </div> <table border="1" style="width: 100%; border-collapse: collapse; margin-top: 5px;"> <tr><td style="height: 20px;"></td><td style="height: 20px;"></td></tr> <tr><td style="height: 20px;"></td><td style="height: 20px;"></td></tr> <tr><td style="height: 20px;"></td><td style="height: 20px;"></td></tr> </table>							

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)								
4	Consulting fees	☒ None <table border="1"> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> </table>									
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	☒ None <table border="1"> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> </table>									
6	Payment for expert testimony	☒ None <table border="1"> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> </table>									
7	Support for attending meetings and/or travel	☒ None <table border="1"> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> </table>									
8	Patents planned, issued or pending	☒ None <table border="1"> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> </table>									
	Participation on a Data Safety Monitoring Board or Advisory Board	☒ None <table border="1"> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> </table>									
ju m p j u m p1 0	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	☒ None <table border="1"> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> <tr><td></td><td></td></tr> </table>									

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
11	Stock or stock options	☒ None	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	☒ None	
13	Other financial or non-financial interests	☒ None	

Please place an "X" next to the following statement to indicate your agreement:

☒ I certify that I have answered every question and have not altered the wording of any of the questions on this form.

Oxue
M